Atossa Therapeutics Announces Regulatory Strategy Aimed at Accelerating Development of Low-Dose (Z)-Endoxifen for Breast Cancer Risk Reduction
1. Atossa requested a Type C FDA meeting for (Z)-endoxifen development. 2. Discussing potential to accelerate approval and cut costs significantly. 3. Market opportunities for (Z)-endoxifen are substantial among breast cancer patients. 4. Direct (Z)-endoxifen avoids tamoxifen's metabolic variability, offering a faster effect. 5. Positive outcomes could enhance ATOS’s valuation and market position.